Insider Frenzy at JPMorgan, Chevron, Eli Lilly, Berkshire, Strategy

Insiders have been trading these 5 stocks: ((JPM)), ((CVX)), ((LLY)), (($BRK.B)) and ((MSTR)). Here is a breakdown of their recent trades and their value.

Senior Insider Shake‑Up: JPMorgan, Chevron, Eli Lilly, Berkshire, Strategy

At JPMorgan Chase, insider selling spans the C‑suite, with CRO Ashley Bacon unloading 4,070 shares for $1,259,339 and CFO Jeremy Barnum selling 3,022 shares worth $935,006. COO Jennifer Piepszak joined the wave, cashing out 4,919 shares for $1,522,036, a trio of transactions that may raise eyebrows about timing and sentiment.

Chevron saw a massive single insider sale as Director John Hess offloaded 195,000 shares of the oil giant, locking in $36,031,212 from the transaction. Such a large disposition in one move can signal personal diversification, but it also puts a spotlight on how he views Chevron’s risk and reward profile at current valuations.

In the pharma space, Former 10% Shareholder Lilly Endowment Inc trimmed its stake in Eli Lilly & Co by selling 15,828 shares, capturing proceeds of $15,754,461. Even modest percentage reductions from a holder of that size can attract attention, as investors watch whether this is routine portfolio management or an early sign of shifting conviction.

Berkshire Hathaway B showed insider confidence from a different angle, with See Remarks insider Michael J. O’Sullivan stepping in to buy 536 shares for $250,545. While small compared with mega‑holders, the purchase stands out because it is a direct bet that Berkshire Hathaway B’s long‑term value outweighs short‑term market noise.

Strategy stock activity centered on Director Jarrod Patten, who executed two notable sales that together reshaped his exposure. He first sold 2,000 shares for $366,500, then followed with a larger 4,000‑share sale worth $676,697, suggesting a deliberate reduction that market watchers will scrutinize for clues about Strategy’s near‑term outlook.